Allesandro Riva, MD

home / authors / allesandro-riva-md

Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Jean-marc A. Nabholtz, MD;Michael Smylie, MD;John R. Mackey, MD;Dick Au, MD;Evelyn Sansregret, MD;Daniel Noel, MD;Alexander H. Paterson, MD;Taher Al-tweigeri, MD;Fernad Delorme, MD;Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

Jean-marc A. Nabholtz, MD;B. Thuerlimann, MD;W. R. Bezwoda, MD;D. Melnychuk, MD;L. Deschênes, MD;J. Douma, MD;T. A. Vandenberg, MD;B. Rapoport, MD;R. Rosso, MD;V. Trillet-lenoir, MD;J. Drbal, MD;Matti S. Aapro, MD;M. Alaki, MD;M. Murawsky, MD;Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of